<div id="readability-page-1"><p><span>CervoMed (NASDAQ:CRVO - Get Free Report)</span>'s stock had its &#34;buy&#34; rating reaffirmed by D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $31.00 price objective on the stock. D. Boral Capital's price target would indicate a potential upside of 236.23% from the stock's previous close.</p><p>Other equities research analysts also recently issued research reports about the company. Zacks Research downgraded CervoMed from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Monday, October 13th. HC Wainwright raised CervoMed from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and raised their price objective for the company from $11.00 to $25.00 in a report on Wednesday, November 5th. Chardan Capital  reaffirmed a &#34;buy&#34; rating and issued a $15.00 target price on shares of CervoMed in a research note on Monday, August 11th. Roth Capital  set a $20.00 price target on shares of CervoMed and gave the company a &#34;buy&#34; rating in a research report on Friday, October 17th. Finally, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of CervoMed in a research note on Wednesday, October 8th. One investment analyst  has rated the stock with a Strong Buy rating, seven have issued  a Buy rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $21.86.</p><p><b>Read Our Latest Research Report on CervoMed</b></p><h2>CervoMed Price Performance</h2><p>CRVO stock opened at $9.22 on Tuesday. CervoMed has a one year low of $1.80 and a one year high of $16.94. The stock has a market cap of $85.31 million, a PE ratio of -3.53 and a beta of -0.89. The firm has a 50 day simple moving average of $7.97 and a two-hundred day simple moving average of $8.14. </p><p>CervoMed (NASDAQ:CRVO - Get Free Report) last posted its quarterly earnings data on Friday, November 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%. The company had revenue of $0.32 million for the quarter, compared to analysts' expectations of $1.43 million.  On average, research analysts expect that  CervoMed will post -1.88 EPS for the current fiscal year. </p><h2>Insider Transactions at CervoMed</h2><p>In other news, CEO John J. Alam purchased 10,807 shares of the company's stock in a transaction on Monday, November 17th. The stock was acquired at an average price of $8.46 per share, with a total value of $91,427.22. Following the transaction, the chief executive officer directly owned 1,484,078 shares of the company's stock, valued at approximately $12,555,299.88. This represents a 0.73% increase in their position. The acquisition was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, Director Sylvie Gregoire purchased 10,807 shares of the business's stock in a transaction on Monday, November 17th. The stock was purchased at an average cost of $8.46 per share, for a total transaction of $91,427.22. Following the acquisition, the director owned 12,500 shares in the company, valued at approximately $105,750. The trade was a 638.33% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 92,000 shares of company stock worth $737,723. Insiders own  35.40% of the company's stock. </p><h2>Hedge Funds Weigh In On CervoMed</h2><p>Several hedge funds and other institutional investors have recently modified their holdings of CRVO. Rhumbline Advisers grew its stake in shares of  CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company's stock worth $53,000 after purchasing an additional 1,526 shares during the last quarter.  GSA Capital Partners LLP purchased a new stake in  CervoMed in the 3rd quarter worth approximately $91,000.  HighTower Advisors LLC bought a new stake in shares of  CervoMed in the 1st quarter worth approximately $104,000.  Marshall Wace LLP purchased a new position in shares of  CervoMed during the second quarter valued at approximately $76,000.  Finally, Bank of New York Mellon Corp purchased a new position in shares of  CervoMed during the first quarter valued at approximately $110,000. 25.15% of the stock is owned by institutional investors. </p><h2>CervoMed Company Profile</h2> (Get Free Report)<p>CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than CervoMed</li><li>Golden Cross Stocks: Pattern, Examples and Charts </li><li>These Are the Hottest Upgrades From the Q3 Reporting Cycle</li><li>Stock Market Upgrades: What Are They?</li><li>Fossil Stock Is Quietly Surging—Insiders Just Made Big Bets</li><li>Short Selling - The Pros and Cons </li><li>Why Bitcoin ETFs Like IBIT May Be Set to Surge in 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CervoMed Right Now?</h2><p>Before you consider CervoMed, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CervoMed wasn't on the list.</p><p>While CervoMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRVO

<p>D. Boral Capital reaffirmed a "buy" rating for CervoMed with a $31.00 price target, indicating a potential upside of 236.23%. Other analysts have mixed ratings, with Zacks Research downgrading to "strong sell" and HC Wainwright upgrading to "buy". The stock opened at $9.22, with a market cap of $85.31 million. Insiders and hedge funds have been actively purchasing shares, with insiders owning 35.40% of the company.</p>

CervoMed's (CRVO) Buy Rating Reaffirmed at D. Boral Capital